These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 31397841)

  • 1. Adrenocortical Carcinoma Xenograft in Zebrafish Embryos as a Model To Study the In Vivo Cytotoxicity of Abiraterone Acetate.
    Gianoncelli A; Guarienti M; Fragni M; Bertuzzi M; Rossini E; Abate A; Basnet RM; Zizioli D; Bono F; Terzolo M; Memo M; Berruti A; Sigala S
    Endocrinology; 2019 Nov; 160(11):2620-2629. PubMed ID: 31397841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study.
    Fiorentini C; Fragni M; Perego P; Vezzoli S; Bonini SA; Tortoreto M; Galli D; Claps M; Tiberio GA; Terzolo M; Missale C; Memo M; Procopio G; Zaffaroni N; Berruti A; Sigala S
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4594-4602. PubMed ID: 27626976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Evidence of Progesterone as a New Pharmacological Strategy in Human Adrenocortical Carcinoma Cell Lines.
    Tamburello M; Abate A; Rossini E; Basnet RM; Zizioli D; Cosentini D; Hantel C; Laganà M; Tiberio GAM; Grisanti S; Memo M; Berruti A; Sigala S
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients.
    Blanchet B; Carton E; Alyamani M; Golmard L; Huillard O; Thomas-Scheomann A; Vidal M; Goldwasser F; Sharifi N; Alexandre J
    Pharmacol Res; 2018 Oct; 136():56-61. PubMed ID: 30142421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models.
    Mariniello B; Rosato A; Zuccolotto G; Rubin B; Cicala MV; Finco I; Iacobone M; Frigo AC; Fassina A; Pezzani R; Mantero F
    Endocr Relat Cancer; 2012 Aug; 19(4):527-39. PubMed ID: 22673336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chloroquine enhances the efficacy of cisplatin by suppressing autophagy in human adrenocortical carcinoma treatment.
    Qin L; Xu T; Xia L; Wang X; Zhang X; Zhang X; Zhu Z; Zhong S; Wang C; Shen Z
    Drug Des Devel Ther; 2016; 10():1035-45. PubMed ID: 27022243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.
    Zhu Y; Wang M; Zhao X; Zhang L; Wu Y; Wang B; Hu W
    Oncotarget; 2017 Apr; 8(14):22825-22834. PubMed ID: 28423559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer.
    Li R; Evaul K; Sharma KK; Chang KH; Yoshimoto J; Liu J; Auchus RJ; Sharifi N
    Clin Cancer Res; 2012 Jul; 18(13):3571-9. PubMed ID: 22753664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 3D adrenocortical carcinoma tumor platform for preclinical modeling of drug response and matrix metalloproteinase activity.
    Dedhia PH; Sivakumar H; Rodriguez MA; Nairon KG; Zent JM; Zheng X; Jones K; Popova LV; Leight JL; Skardal A
    Sci Rep; 2023 Sep; 13(1):15508. PubMed ID: 37726363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells.
    De Martino MC; van Koetsveld PM; Feelders RA; Sprij-Mooij D; Waaijers M; Lamberts SW; de Herder WW; Colao A; Pivonello R; Hofland LJ
    Endocr Relat Cancer; 2012 Jun; 19(3):351-64. PubMed ID: 22420007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trabectedin impairs invasiveness and metastasis in adrenocortical carcinoma preclinical models.
    Abate A; Tamburello M; Rossini E; Basnet RM; Ribaudo G; Gianoncelli A; Hantel C; Cosentini D; Laganà M; Grisanti S; Tiberio GAM; Memo M; Berruti A; Sigala S
    Endocr Relat Cancer; 2023 Feb; 30(2):. PubMed ID: 36449565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abiraterone Acetate for Cushing Syndrome: Study in a Canine Primary Adrenocortical Cell Culture Model.
    Sanders K; de Wit WL; Mol JA; Kurlbaum M; Kendl S; Kroiss M; Kooistra HS; Galac S
    Endocrinology; 2018 Nov; 159(11):3689-3698. PubMed ID: 30219917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.
    Barlaskar FM; Spalding AC; Heaton JH; Kuick R; Kim AC; Thomas DG; Giordano TJ; Ben-Josef E; Hammer GD
    J Clin Endocrinol Metab; 2009 Jan; 94(1):204-12. PubMed ID: 18854392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
    Doghman M; Lalli E
    Mol Cell Endocrinol; 2013 Dec; 381(1-2):66-9. PubMed ID: 23906534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane.
    van Koetsveld PM; Vitale G; Feelders RA; Waaijers M; Sprij-Mooij DM; de Krijger RR; Speel EJ; Hofland J; Lamberts SW; de Herder WW; Hofland LJ
    Endocr Relat Cancer; 2013 Jun; 20(3):443-54. PubMed ID: 23507702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma.
    Xu L; Qi Y; Xu Y; Lian J; Wang X; Ning G; Wang W; Zhu Y
    Oncotarget; 2016 Jun; 7(24):36235-36246. PubMed ID: 27105537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene.
    Creemers SG; van Koetsveld PM; van den Dungen ES; Korpershoek E; van Kemenade FJ; Franssen GJ; de Herder WW; Feelders RA; Hofland LJ
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4574-4584. PubMed ID: 27603910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin as a new anti-cancer drug in adrenocortical carcinoma.
    Poli G; Cantini G; Armignacco R; Fucci R; Santi R; Canu L; Nesi G; Mannelli M; Luconi M
    Oncotarget; 2016 Aug; 7(31):49636-49648. PubMed ID: 27391065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment.
    Sirianni R; Zolea F; Chimento A; Ruggiero C; Cerquetti L; Fallo F; Pilon C; Arnaldi G; Carpinelli G; Stigliano A; Pezzi V
    J Clin Endocrinol Metab; 2012 Dec; 97(12):E2238-50. PubMed ID: 23074235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC).
    Casaburi I; Avena P; De Luca A; Chimento A; Sirianni R; Malivindi R; Rago V; Fiorillo M; Domanico F; Campana C; Cappello AR; Sotgia F; Lisanti MP; Pezzi V
    Oncotarget; 2015 Sep; 6(28):25135-48. PubMed ID: 26312764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.